Building on these advances in DC vaccination, the response to anti-CTLA-4 blockade in poorly immunogenic tumours is contingent on DC activation, which was previously accomplished through GM-CSF vaccination, mimicking a typical ‘hot’ tumour state [20, 21]. The gene discussed is CTLA4; the disease is neoplasm.